ARYx leads with $30.4 million
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
ARYx Therapeutics
|
$30.4 million
|
Ascent Biomedical Ventures |
ARYx has three trials underway for ATI-7505, a treatment for gastroesophageal reflux disease; ATI-2042, a treatment for atrial fibrillation, and ATI-5923, an oral anti-coagulant currently in Phase 1. |
|
Catalyst Biosciences
|
$30 million
|
Morgenthaler Ventures |
Catalyst's product discovery platform includes methods to rapidly create and optimize tailor-made protease drug candidates, called Alterases. |
|
vasopharm Biotech
|
$11.8 million
|
EMBL Ventures |
The money is earmarked to support the further clinical development of vasopharm's compound VAS 203, a nitric oxide synthase (NOS) inhibitor for the treatment of closed head injury. |
|
InnoCentive
|
$9 million
|
Spencer Trask Ventures |
InnoCentive--created by Eli Lilly--has been developing a network of scientists to tackle scientific problems posted online for cash rewards. |
|
Accumetrics
|
$8.25 million
|
RiverVest Venture Partners |
The company makes a family of diagnostic tests that measure platelet function. |